S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Synthetic Biologics to Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day|
|Luxoft Holding Announces a Proposed Reorganization of its Majority Shareholder, IBS Group Holding, Involving an Exchange of a Portion of IBS Group's Share Capital for a Portion of its Shares in Luxoft|
|Synthetic Biologics to Host Irritable Bowel Syndrome (IBS) Investor Day|
|Excalibur Ib enters full rate production and receives $52 million award|
|Synthetic Biologics Reports that Licensor Cedars-Sinai Finds Eradication of Gut Methane Improves Insulin Sensitivity and Lipid Profiles in Study of Pre-Diabetic, Obese Patients (2014/6/25)|
|Synergy Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Plecanatide in Irritable Bowel Syndrome with Constipation|
|Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline|
|Cara Therapeutics Initiates Phase Ia/Ib Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain|
|Salix Announces Important Topline Results for Microbiome, Culture & Susceptibility, and Key Secondary Efficacy Results for TARGET 3, Rifaximin IBS-D Repeat Treatment Study|
|Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights (2014/8/14)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
Click above to view more mutual fund data and stats for ibs - Ibersol SGPS SA.